Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
Plain-language summary
This trial is testing chidamide (an oral HDAC inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide) (DRUG): 3 cycles of BvC treatment for all enrolled patients. Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.; Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.; | Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide) (DRUG): Consolidation therapy( For patients who achieved CR after induction therapy, 3 cycles of additional BvC treatment; For patients who achieved PR after induction therapy, 6 cycles of additional BvC treatment). Brentuximab vedotin; Specification: 50mg per vial; 1.8mg/kg qd d1 every 3 weeks, ivgtt.; Chidamide; Specification: 5mg per tablet; 20mg biw for 2 weeks every 3 weeks, po.; Maintenance therapy chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years | Maintenance therapy-chidamide (DRUG): Chidamide (20mg biw for 2 weeks every 3 weeks, po.) for ≥2 years
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide), Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide), Maintenance therapy-chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details